Compare ZTS & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTS | BDX |
|---|---|---|
| Founded | 1952 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.7B | 51.5B |
| IPO Year | 2012 | 1994 |
| Metric | ZTS | BDX |
|---|---|---|
| Price | $121.63 | $161.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $156.20 | ★ $189.60 |
| AVG Volume (30 Days) | ★ 3.3M | 2.2M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | 1.74% | ★ 2.60% |
| EPS Growth | ★ 10.05 | N/A |
| EPS | ★ 6.02 | 1.34 |
| Revenue | $9,467,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $5.69 | N/A |
| Revenue Next Year | $4.81 | $2.53 |
| P/E Ratio | ★ $20.21 | $120.46 |
| Revenue Growth | 2.28 | ★ 8.24 |
| 52 Week Low | $114.47 | $158.20 |
| 52 Week High | $172.23 | $231.82 |
| Indicator | ZTS | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 27.90 |
| Support Level | $117.42 | N/A |
| Resistance Level | $130.52 | $177.73 |
| Average True Range (ATR) | 3.20 | 3.82 |
| MACD | -0.75 | -0.54 |
| Stochastic Oscillator | 40.38 | 13.34 |
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.